2024-03-29T15:40:38Zhttp://repisalud.isciii.es/oai/requestoai:repisalud.isciii.es:20.500.12105/82352022-11-11T16:29:10Zcom_20.500.12105_2060com_20.500.12105_2052com_20.500.12105_2051col_20.500.12105_2061
00925njm 22002777a 4500
dc
de la Campa, Adela G
author
Ferrandiz-Avellano, Maria-Jose
author
Tubau, Fe
author
Pallarés, Román
author
Manresa, Federico
author
Liñares, Josefina
author
2003-04
Five Spain(9V-3) Streptococcus pneumoniae strains were isolated from a patient with bronchiectasis who had received long-term ciprofloxacin therapy. One ciprofloxacin-susceptible strain was isolated before treatment, and four ciprofloxacin-resistant strains were isolated during treatment. The resistant strains were derived from the susceptible strain either by a parC mutation (low-level resistance) or by parC and gyrA mutations (high-level resistance). This study shows that ciprofloxacin therapy in a patient colonized by susceptible S. pneumoniae may select fluoroquinolone-resistant mutants.
Antimicrob Agents Chemother. 2003 Apr;47(4):1419-22.
0066-4804
http://hdl.handle.net/20.500.12105/8235
12654682
10.1128/aac.47.4.1419-1422.2003
Antimicrobial agents and chemotherapy
Genetic characterization of fluoroquinolone-resistant Streptococcus pneumoniae strains isolated during ciprofloxacin therapy from a patient with bronchiectasis